Analytical Data
-
Gene name
VSIR
- Application
-
Alternative Names
VSIR；C10orf54；V-type immunoglobulin domain-containing suppressor of T-cell activation
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H7M9
-
Expression Region
33-194aa
-
AA Sequence
FKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQESENITAA
-
Molecular Weight
23.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VSIR, or V-set and immunoglobulin domain containing 1, is a protein that plays a significant role in immune regulation. Found predominantly on the surface of immune cells, particularly in dendritic cells and macrophages, VSIR functions as a coinhibitory receptor that modulates T-cell responses. The research surrounding VSIR has gained momentum as it is implicated in various pathological conditions, including cancer and autoimmune diseases. Understanding the mechanisms through which VSIR interacts with its ligands, such as programmed death-ligand 1 (PD-L1), is crucial for deciphering its role in the immune checkpoint pathway. Studies have demonstrated that VSIR can inhibit T-cell activation and induce apoptosis in activated T-cells, making it a potential target for therapeutic interventions aimed at enhancing anti-tumor immunity or restoring immune tolerance in autoimmune disorders. Additionally, the exploration of VSIR as a biomarker for disease prognosis and treatment response further underscores its importance in translational research. As the field of immunotherapy continues to evolve, VSIR-recombinant proteins are being investigated in preclinical models to assess their efficacy in modulating immune responses, paving the way for novel therapeutic strategies. This research not only holds promise for cancer treatment but also presents opportunities to improve outcomes in various immune-related diseases. Through comprehensive studies involving VSIR and its pathways, researchers aim to harness the power of immune modulation to develop innovative treatments and improve patient outcomes in complex diseases where the immune system plays a pivotal role.
